152 related articles for article (PubMed ID: 34215931)
21. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA; Schoenfeld AJ; Makhnin A; Kim R; Rizvi H; Tsui D; Falcon C; Houck-Loomis B; Meng F; Yang JL; Tobi Y; Heller G; Ahn L; Hayes SA; Young RJ; Arcila ME; Berger M; Chaft JE; Ladanyi M; Riely GJ; Kris MG
JAMA Oncol; 2020 Jul; 6(7):1048-1054. PubMed ID: 32463456
[TBL] [Abstract][Full Text] [Related]
22. Osimertinib plus Ramucirumab: The Best of Both Worlds?
Garon EB
Clin Cancer Res; 2021 Feb; 27(4):905-907. PubMed ID: 33334907
[TBL] [Abstract][Full Text] [Related]
23. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
[TBL] [Abstract][Full Text] [Related]
24. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
[TBL] [Abstract][Full Text] [Related]
25. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
26. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
29. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
30. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
31. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
[TBL] [Abstract][Full Text] [Related]
32. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
Xing P; Mu Y; Hao X; Wang Y; Li J
Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.
Akamatsu H; Koh Y; Ozawa Y; Fujimoto D; Hata A; Katakami N; Tomii K; Shimokawa T; Yamamoto N
Clin Lung Cancer; 2018 Nov; 19(6):e871-e874. PubMed ID: 30197264
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial evaluating efficacy and safety of pemetrexed based chemotherapy regimen versus ramucirumab plus erlotinib in Chinese patients with lung cancer: A preliminary investigation.
Mei Q; Ye L; Chen C; Lin H
Pak J Pharm Sci; 2020 Sep; 33(5(Special)):2379-2384. PubMed ID: 33832878
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
36. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
